Sumary of Study explores adverse effects of SARS-CoV-2-induced antibody responses:
- Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggers an immune response driven by the immunoglobulin G (IgG) family of antibodies in the infected individual.
- This response against the SARS-CoV-2 receptor-binding domain (RBD) is driven primarily by IgG1 and IgG3 sub-classes.
- While several studies have established the positive outcomes of this antibody-mediated viral neutralization, its potential adverse effects are yet unknown.
- Study: SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
- Image Credit: Juan Gaertner / Shutterstock The study included a total of 180 people who recovered from coronavirus disease 2019 (COVID-19), as confirmed by their negative reverse transcription-polymerase chain reaction (RT-PCR) test.
- The RT-PCR positive participants comprised males and females in the age group 18–86, with the course of disease ranging from mild (few symptoms) to severe (needed hospitalization).
- Healthy blood donors were used as negative controls to collect a total of 60 EDTA plasma samples (from before 2020) having no SARS-CoV-2 antibodies.
- Assessing levels of IgG sub-classes and complement molecules During natural infection, IgG1 and IgG3 sub-classes effectively activate the classical complement pathway to eliminate the pathogen (here SARS-CoV-2) employing methods such as microbial lysis by the terminal complement complex (TCC).